The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved abemaciclib (Verzenio) with endocrine therapy (tamoxifen or...
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced...
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) for the treatment of adult patients with...
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved elacestrant (Orserdu) for the treatment of men and...
The FDA granted accelerated approval to the BTK inhibitor pirtobrutinib for the treatment of mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
Pembrolizumab was approved to treat some patients with lung cancer after surgery and chemotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the adjuvant treatment of stage IB, II, or...
The FDA approved tucatinib for certain patients with unresectable or metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab for the treatment...
The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ...
The FDA granted accelerated approval to mosunetuzumab-axgb, the first bispecific antibody approved to treat a form of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mosunetuzumab-axgb (Lunsumio) for...
The FDA approved the adenovirus-based gene therapy nadofaragene firadenovec for the treatment of localized bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nadofaragene firadenovec (Adstiladrin) for the treatment of adult patients...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More